Zymeworks reports 41.3% cORR for zanidatamab in HER2-amplified BTC from Phase 2b trial

Zymeworks Inc.

cORR of 41.3% (95% CI: 30.4-52.8) in Cohort 1 (IHC 2+/3+) by independent central review.
Median duration of response 12.9 months; median progression-free survival 5.5 months.
48.5% of responders had ongoing responses at October 10, 2022 data cutoff.
Only 2.3% of patients discontinued treatment due to adverse events; no Grade 4 or treatment-related deaths.
Data presented at ASCO 2023 and concurrently published in The Lancet Oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.